share_log

Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density

Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density

Atossa Therapeutics 宣布将在2024年圣安东尼奥乳腺癌研讨会上展示第二阶段KARISMA-Endoxifen研究的完整结果;显示出乳腺X光摄影密度的统计学显著降低。
Benzinga ·  12/11 21:17

Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density

Atossa Therapeutics 宣布将在2024年圣安东尼奥乳腺癌研讨会上展示第二阶段KARISMA-Endoxifen研究的完整结果;显示出乳腺X光摄影密度的统计学显著降低。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发